As Greater Boston’s biotech industry sheds jobs, three unlikely regions are showing promise as up-and-coming hubs.
Source: BioPharma Dive
You may also like
Vera Therapeutics wins FDA nod for closely watched...
Gene editing developer Scribe plots an IPO
Novartis to acquire ADC developer in a deal worth up...
Novartis to pay $1.1B upfront for UK biotech Myricx to...
Genentech lays off 103 alongside gRED rethink, pens...
Scribe notes down IPO ambition to fund lipid-lowering...
About the author
David Miller
a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.